Klein brings a wealth of expertise to this role, having served in a number of senior leadership capacities over the past 14 years at Constellation Brands. His capabilities include extensive CPG and beverage alcohol industry experience, strong financial orientation, and experience operating in highly regulated markets in the U.S., Canada, Mexico and Europe.

Klein is an experienced strategist with a deep understanding
of how to build enduring consumer brands while leveraging operational scale
across a dispersed production footprint. He is a strong leader with a proven
track record of developing diverse and high performing teams.

Canopy Growth sits at the forefront of one of the most exciting new market opportunities in our lifetime.

Canopy Growth CEO, David Klein

The company also revealed its upcoming Cannabis 2.0 portfolio
of products, which are set to come to market as part of the second wave of
Canadian cannabis commercialization. With December 16, 2019, being the first
date new product formats can be sold into distribution channels. The Company
expects that in most markets new products will not be seen on shelves until
early in January 2020.

Leveraging learnings from Cannabis 1.0, the Company will
stagger its launch of various products and formats to ensure a smooth roll-out.
As such, availability will vary by province based on their individual ordering
and distribution activities. While the Company is providing this update in
advance of the launch of Cannabis 2.0 products, for competitive reasons, it
will not provide ongoing updates during the actual rollout period.

The first wave of cannabis chocolate products, which will
arrive in retail in early January 2020, includes Tokyo Smoke Go, Tokyo Smoke
Pause, and Tweed Bakerstreet chocolate bars. Tokyo Smoke Go is a THC-infused,
sativa-dominant dark milk chocolate with minimal CBD content.

This week Canopy Growth also marked its first official
entrance into the US market through the
launch of its new CBD brand 'First & Free'. Canopy's new CBD line will
be available in the 31 U.S. states where CBD products are legal for sale, and
the company reports it has filled 40 provisional patents and conducted 11
therapeutic trials.

The opening of the company's new brand comes after an
announcement made in early 2019, when CGC delighted investors with the news
that it was going to invest between USD$100-$150 million to establish a hemp
industrial park just outside of New York City.

The market liked this move and the Canopy Growth stock price really climbed. This was one of the few times that Canopy has demonstrated slow, methodical, well thought out, growth. No rash and overvalued purchases. This is because hemp is part and parcel with creating CBD products, as they are almost always hemp-derived due to the plant's lower THC content.

The former head of Canopy Growth, Bruce Linton, discusses the company's new CEO

Under these State Licences, MediPharm Labs Australia is allowed to store, test
and supply cannabis for research purposes at its newly built facility.
Construction of the 10,000 square foot plant began 18 months ago.

The final stage of regulatory approvals is now underway and is expected in H1
2020, which will make MediPharm Labs Australia a first mover in the Australian
market for the manufacture of cannabis derivative products.

We envisioned that MediPharm Labs Australia would be a pioneering leader in the supply of high-quality, pharmaceutical-like cannabis derivative products for the domestic Australian and international export markets

With the recent growth of the state's medical market and
adult-use legalization going live on January 1st, Cresco has been scaling
operations to be able to accommodate what is expected to be one of the largest
cannabis markets in the country. To date, Cresco has been able to capture an
approximate 25% market share through its original 35,000 square feet of
aggregate cultivation space across its three facilities.

Earlier this year, after the expansion of the medical
program and the passing of adult-use legislation, the Company embarked on an
ambitious expansion plan that will bring the total area under cultivation to
approximately 243,000 square feet by year-end.

Under the terms of the letter agreement, Dycar will provide
Indiva with initial non-dilutive financing of $3.1 million, and Indiva will
manufacture and distribute certain Dycar-branded cannabis products from the
Company's licensed facility in London, Ontario.

The financing will be repaid by the deduction of Indiva
services in kind to Dycar. The letter agreement may be renewed at the option of
Dycar for a minimum of two additional terms, resulting in up to $4.5 million of
additional non-dilutive financing. Indiva anticipates that it will begin the
production of Dycar branded products in Q1 2020.

Dycar and Indiva are very much aligned in our shared pursuit of delivering the very best products to market. We are very excited to begin working with the Dycar team and creating new products that meet and exceed customer and consumer expectations.

Bayern brings over 20 years of executive leadership
experience in consumer packaged goods at a critically important moment in
Curaleaf's growth trajectory. He will report to Curaleaf Chief Executive
Officer Joseph Lusardi.

As President, Bayern will work closely with the senior
executive team to lead the company and oversee its continued growth. Bayern
will primarily be focused on driving operational excellence and executing on
Curaleaf's mission. CEO Joseph Lusardi will continue to oversee the strategic
vision and operations of the company.

The GMP certification was issued by Infarmed, the Portuguese
National Authority of Medicines and Health Products. This is the second GMP
certification for Tilray Portugal, which allows the facility to manufacture and
export GMP-certified finished medical cannabis products, including dried flower
and oils, from Portugal to international markets with legal medical cannabis
regulations.

Tilray's EU campus in Portugal is a multi-faceted production
facility that includes outdoor and greenhouse cultivation sites; research and
quality control labs; and processing, packaging and distribution sites for
medical cannabis.

According to Medlab's website, ORSBiotic "contains
selected probiotic species which can help maintain gastrointestinal
homeostasis. Saccharomyces boulardii and zinc have clinical evidence for
providing therapeutic support for various triggers of diarrhoea and may help
reduce the occurrence of diarrhoea in children."

NanoCBD is a hemp-derived CBD formulation that contains
16.67 mg/mL cannabidiol (CBD) as an active ingredient, in a sub-micron spray
applied to the oro-buccal membrane. The product is designed to help with
anxiety and inflammation.

I have worked with [Cultech] for well over a decade and they are uniquely placed to expand trade into territories beyond the United Kingdom.

The product line, from award-winning brand Evolab includes
Chroma, Alchemy and Delta 8, all of which utilize a distillation process
resulting in an extract that is 100% cannabis-derived, free from cutting agents
using instrument grade CO2—considered a clean extraction method.

Harvest recently announced its commitment to creating,
high-quality and trusted vaporizer products under the rigorous CannApprove
testing protocol.

Harvest CEO and Co-Founder Steve White discusses the company is working to satisfy the Department of Justice in its proposed acquisition of Verano Holdings.

Pursuant to the Definitive Agreement, High Tide, which
presently holds a controlling interest of 50.1% in KushBar, will acquire the
Minority Interest in a transaction that will result in KushBar becoming a
wholly-owned subsidiary of High Tide.

The Transaction marks a crucial step in High Tide's strategy
to capitalize on the second wave of the legalization of recreational cannabis
products, including but not limited to concentrates, edibles and infused
beverages, which are expected to be available in Alberta in early 2020.

As we move closer towards the new year, we are excited for what Cannabis 2.0 will have in store for High Tide and its customers

Each Unit will consist of one common share in the capital of
the company and one Common Share purchase warrant. Each Warrant will be
exercisable to acquire one Common Share for a period of 24 months following the
closing of the Offering at an exercise price of CAD$3.25 per Warrant Share.

The Company intends to use the proceeds from the Private
Placement to accelerate the completion of the New Jersey cultivation and
processing facilities and to make the previously announced January 2020
contingent purchase price payment related to the acquisition of Ilera
Healthcare. Proceeds may also be used for working capital and general corporate
purposes.

I want to learn more about…

CannabisLatest Stock Picks

I want to learn more about…

CannabisLatest Stock Picks

The Green Fund is Asia Pacific's preeminent media house, positioned at the forefront of the global cannabis industry. Committed to driving the industry forward, we spotlight the sector from all angles, explore the companies and the players making headlines, and cover some of the biggest cannabis companies in the world.

Any financial product advice provided in this website is general in nature. Content on this website does not take into account the objectives, financial situation or needs of any person, or purport to be comprehensive or constitute investment advice and should not be relied upon as such. You should consult a professional adviser to help you form your own opinion of the information and on whether the information is suitable for your individual objectives and needs as an investor. Where necessary, you should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product. Read More

The content of this website does not constitute an offer by any representative of The Green Fund to buy or sell any financial products or services. Accordingly, reliance should not be placed solely on the content of this website, including any reports or recommendations, as the basis for making an investment, financial or other decision.

Recipients should not act on any report or recommendation issued by The Green Fund without first consulting a professional advisor in order to ascertain whether the recommendation (if any) is appropriate, having regard to their investment objectives, financial situation and particular needs. Any opinions expressed are subject to change without notice and may not be updated by The Green Fund.

The Green Fund believes the information contained in this website is correct. All information, opinions, conclusions, estimates, reports or recommendations provided are included with due care to its accuracy; however, no representation or warranty is made as to their accuracy, completeness, or reliability.

The Green Fund disclaims all liability and responsibility for any direct or indirect loss, or damage, which may be incurred by any recipient through any information, omission, error, or inaccuracy contained within any report or recommendation.

The views expressed in any report or recommendation are those of the analyst writing the report and no part of the compensation received by the analyst is directly related to the inclusion of specific recommendations or opinions.

The Green Fund and / or its associates may hold interests in the entities mentioned in any posted report or recommendation.

The Green Fund, or its representatives, may have relationships with the companies mentioned in posted reports - for example, acting as corporate advisor, dealer, broker, or holder of principal positions. The Green Fund and / or its representatives may also transact in those securities mentioned in the report, in a manner not consistent with recommendations made in the report.

Any recommendations or opinions stated in a report are done so based on assumptions made by The Green Fund.

The information provided in any report and on which it is based may include projections and / or estimates which constitute forward-looking statements. These expressed beliefs of future performance, events, results, or returns may not eventuate and as such no guarantee of these future scenarios is given or implied by The Green Fund. Any forward looking statements are subject to uncertainties and risks that may mean those forecasts made by The Green Fund are materially different to actual events. Show Less